Skip to main content
. 2015 May 1;4:14. doi: 10.1186/s13756-015-0055-6

Table 3.

Baseline characteristics of patients given definitive monotherapy with a BLBLI or carbapenem

Patient characteristic Definitive treatment cohort Total study population
BLBLI (N = 24) Carbapenem (N = 23) N = 91
Age, median [IQR], years 77 [61–83] 77 [68–83] 75 [62–83]
Female 13 (54%) 12 (52%) 49 (54%)
Hospital acquired 7 (29%) 4 (17%) 20 (22%)
Community acquired 7 (29%) 9 (39%) 42 (46%)
Healthcare associated 10 (42%) 10 (43%) 29 (32%)
CCI, median [IQR] 2 [1-4] 2 [1-5] 2 [1-4]
Pitt score, median [IQR] 1 [0–2] 1 [0–3] 1 [0–2]
APACHEII (if ICU), median [IQR] 26 20 24 [15-28]
ICU admission 2 (8%) 5 (22%) 11 (12.1)
E. coli 22 (92%) 17 (74%) 79 (87%)
Source:
Hepato-biliary 2 (8%) 2 (9%) 12 (13%)
Urinary tract 9 (38%) 13 (57%) 43 (47%)
Neutropenic sepsis 1 (4%) 0 (0%) 4 (4%)
Other/unknown source 12 (50%) 8 (34%) 32 (35%)
Co-morbidity/devices:
Moderate to severe liver disease 3 (13%) 1 (4%) 7 (8%)
Diabetes without end organ damage 6 (25%) 5 (22%) 21 (23%)
Diabetes with organ damage 4 (17%) 5 (22%) 15 (17%)
Moderate to severe renal disease 4 (17%) 7 (31%) 19 (21%)
Metastatic solid tumour 1 (4%) 1 (4%) 4 (4%)
Leukaemia or lymphoma 1 (4%) 2 (9%) 7 (8%)
Urinary device 5 (21%) 3 (13%) 15 (17%)
Immunosuppressive treatments 2 (8%) 4 (17%) 12 (13%)
Empirical therapy:
3GC 7 (29%) 6 (26%) 33 (36%)
BLBLI 11 (46%) 5 (22%) 25 (28%)
Carbapenem 0 (0%) 2 (9%) 8 (9%)
Other* 6 (25%) 10 (43%) 25 (27%)
Appropriate empirical therapy 15 (63%) 15 (65%) 50 (55%)

*Including combinations of carbapenem/BLBLI/3CG.

CCI = Charlson Co-morbidity index, IQR = Inter-quartile range, ICU = intensive care unit, 3GC = third-generation cephalosporins, BLBLI = beta-lactam/beta-lactamase inhibitor.